<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03198052</url>
  </required_header>
  <id_info>
    <org_study_id>CAR-T on lung cancer</org_study_id>
    <nct_id>NCT03198052</nct_id>
  </id_info>
  <brief_title>HER2/Mesothelin/Lewis-Y/PSCA/MUC1/GPC3/AXL/EGFR/B7-H3/Claudin18.2-CAR-T Cells Immunotherapy Against Cancers</brief_title>
  <official_title>CAR-T Cells Targeting HER2, Mesothelin, Lewis-Y, PSCA, MUC1, GPC3, AXL, EGFR, B7-H3 or Claudin18.2 for Immunotherapy of Lung Cancer: Phase I Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital of Guangzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hunan Zhaotai Yongren Medical Innovation Co. Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangdong Zhaotai InVivo Biomedicine Co. Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Second Affiliated Hospital of Guangzhou Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The third generation of CAR-T cells that target HER2, Mesothelin, Lewis-Y, PSCA, MUC1, GPC3,&#xD;
      AXL, EGFR, or B7-H3 have been constructed respectively and their anti-cancer function has&#xD;
      been verified by multiple in vitro and in vivo studies.Clinical studies will be performed to&#xD;
      test the anti-cancer function of the these individual or combination of the CAR-T cells for&#xD;
      immunotherapy of human cancer patients with HER2, Mesothelin, Lewis-Y, PSCA, MUC1, GPC3, AXL,&#xD;
      EGFR, or B7-H3 expressions. In this phase I study, the safety, tolerance, and preliminary&#xD;
      efficacy of the HER2/Mesothelin/Lewis-Y/PSCA/MUC1/GPC3/AXL/EGFR/B7-H3 -CAR-T cell&#xD;
      immunotherapy on human cancers will firstly be tested.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Choose appropriate patients with advanced lung or other cancers,with written consent for&#xD;
           this study;&#xD;
&#xD;
        2. Perform biopsy to determine the expression of HER2, Mesothelin, Lewis-Y, PSCA, MUC1,&#xD;
           GPC3, AXL, EGFR, Claudin18.2, or B7-H3 of the tumor by western blotting or IHC;&#xD;
&#xD;
        3. Collect blood from the patients and isolate mononuclear cells, activate the T cells and&#xD;
           transfect the T cells with HER2, Mesothelin, Lewis-Y, PSCA, MUC1, GPC3, AXL, EGFR,&#xD;
           Claudin18.2, or B7-H3 targeting CAR, amplify the transfected T cells as needed, test the&#xD;
           quality and killing activity of the CAR-T cells and then transfer them back the patients&#xD;
           via systemic or local injections, and follow up closely to collect related results as&#xD;
           needed;&#xD;
&#xD;
        4. To enhance the killing capability, CD4+ T cells are genetically engineered to express&#xD;
           TGFβ-CAR and secret IL7/CCL19 and/or SCFVs against PD1/CTLA4/Tigit; CD8+T cells are&#xD;
           constructed to express HER2/Mesothelin/Lewis-Y/PSCA/MUC1/&#xD;
           GPC3/AXL/EGFR/Claudin18.2/B7-H3-DAP10-CAR with knockdown of PD1/HPK1;&#xD;
&#xD;
        5. Other cancers with these cell surface antigen expressions are also recruited if needed;&#xD;
&#xD;
        6. Evaluate the clinical results as needed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2017</start_date>
  <completion_date type="Anticipated">August 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Use engineered CAR-T cells to kill cancer cells with certain targets.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients with Dose Limiting Toxicity</measure>
    <time_frame>three months</time_frame>
    <description>A dose limiting toxicity is defined as any toxicity that is considered to be primarily related to the PSCA/MUC1/GPC3/AXL/EGFR/B7-H3 -CAR T cells,which is irreversible, or life threatening or hematologic or non-hematologic Grade 3-5.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of Patients with best response as either complete remission or partial remission.</measure>
    <time_frame>three months</time_frame>
    <description>Response rates will be estimated as the percent of patients whose best response is either complete remission or partial remission by combining the data from the patients. To compare with historical data, a 95% confidence interval will be calculated for the response rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median CAR-T cell persistence</measure>
    <time_frame>Six years</time_frame>
    <description>Median CAR-T cell persistence will be measured by quantitative rt-PCR.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Lung Cancer</condition>
  <condition>Cancer</condition>
  <condition>Immunotherapy</condition>
  <condition>CAR-T Cell</condition>
  <arm_group>
    <arm_group_label>CAR-T cell therapy group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive 3 or more cycles of the CAR-T cells treatment via systemic or regional injection, from 1x10e6/kg-10x10e6/kg weight.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CAR-T cells targeting HER2, Mesothelin, PSCA, MUC1, Lewis-Y, GPC3, AXL, EGFR, Claudin18.2, or B7-H3</intervention_name>
    <description>CAR-T cells injection: (1-10×10e6/kg CAR-T for each treatment; 3 or more cycles.</description>
    <arm_group_label>CAR-T cell therapy group</arm_group_label>
    <other_name>Administration of CAR-T cells through vein or interventional technique.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1. Patients with advanced cancer that expresses PSCA, MUC1, GPC3, AXL, EGFR or B7-H3&#xD;
        protein; 2. Life expectancy &gt;12 weeks; 3. Adequate heart,lung,liver,kidney function; 4.&#xD;
        Available autologous transduced T cells with greater than or equal to 20% expression of&#xD;
        PSCA, MUC1, GPC3, AXL, EGFR or B7-H3 CAR determined by flow-cytometry and killing of&#xD;
        PSCA,MUC1,GPC3, AXL, EGFR, or B7-H3 -positive targets greater than or equal to 20% in&#xD;
        cytotoxicity assay; 5. Informed consent explained to, understood by and signed by&#xD;
        patient/guardian. Patient/guardian given copy of informed consent.&#xD;
&#xD;
        -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Had accepted gene therapy before;&#xD;
&#xD;
          2. Severe virus infection such as HBV,HCV,HIV,et al;&#xD;
&#xD;
          3. Known HIV positivity;&#xD;
&#xD;
          4. Active infectious disease related to bacteria, virus,fungi,et al;&#xD;
&#xD;
          5. Other severe diseases that the investigators consider not appropriate;&#xD;
&#xD;
          6. Pregnant or lactating women;&#xD;
&#xD;
          7. Systemic steroid treatment (greater than or equal to 0.5 mg prednisone&#xD;
             equivalent/kg/day);&#xD;
&#xD;
          8. Other conditions that the investigators consider not appropriate. -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhenfeng Zhang, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Second Affiliated Hospital of Guangzhou Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhenfeng Zhang, MD,PhD</last_name>
    <phone>0086-020-34153532</phone>
    <email>zhangzhf@gzhmu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Peng Li, PhD</last_name>
    <phone>+86 20 32015300</phone>
    <email>lipeng@invivobio.com.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510072</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xianhong Xiang, MD,PHD</last_name>
    </contact>
    <contact_backup>
      <last_name>Yonghui Huang, MD,PHD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Guangzhou Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510260</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhenfeng Zhang, MD,PhD</last_name>
      <email>zhangzhf@gzhmu.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Deji Chen, MD,PhD</last_name>
      <phone>+86-020-34153532</phone>
      <email>chendeji2003@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Wei X, Lai Y, Li J, Qin L, Xu Y, Zhao R, Li B, Lin S, Wang S, Wu Q, Liang Q, Peng M, Yu F, Li Y, Zhang X, Wu Y, Liu P, Pei D, Yao Y, Li P. PSCA and MUC1 in non-small-cell lung cancer as targets of chimeric antigen receptor T cells. Oncoimmunology. 2017 Feb 6;6(3):e1284722. doi: 10.1080/2162402X.2017.1284722. eCollection 2017.</citation>
    <PMID>28405515</PMID>
  </results_reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>June 22, 2017</study_first_submitted>
  <study_first_submitted_qc>June 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 23, 2017</study_first_posted>
  <last_update_submitted>November 28, 2020</last_update_submitted>
  <last_update_submitted_qc>November 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lung Cancer</keyword>
  <keyword>CAR-T Cell Therapy</keyword>
  <keyword>PSCA</keyword>
  <keyword>MUC1</keyword>
  <keyword>HER2</keyword>
  <keyword>Mesothelin</keyword>
  <keyword>Lewis-Y</keyword>
  <keyword>GPC3</keyword>
  <keyword>AXL</keyword>
  <keyword>EGFR</keyword>
  <keyword>B7-H3</keyword>
  <keyword>Claudin18.2</keyword>
  <keyword>TGFβ</keyword>
  <keyword>DAP10</keyword>
  <keyword>HPK1</keyword>
  <keyword>PD1</keyword>
  <keyword>CTLA4</keyword>
  <keyword>Tigit</keyword>
  <keyword>Knockdown</keyword>
  <keyword>SCFV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

